NL-OMON56319尚未招募3 期
Clinical Performance Study Protocol for Use of VENTANA PD-L1 (SP263) CDx Assay in AstraZeneca Study D798AC00001(eVOLVE-Lung02): A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02) - eVOLVE-Lung02
Astra Zeneca0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. It must be an FFPE tumor specimen submitted for AstraZeneca Study
- •eVOLVE-Lung02 under appropriate patient informed consent and processed in
- •accordance with standard practice;
- •2. It must contain sufficient tissue for interpretation at the discretion of
- •the reviewing pathologist; and
- •3. If an FFPE tissue block is unavailable, unstained FFPE slides can be
排除标准
- •A specimen will be excluded from staining with the investigational essay if any
- •of the following conditions apply:
- •1. It was known to be fixed in alcohol-formalin-acetic acid (AFA), 95% alcohol
- •or any other alcohol-based fixative, or;
- •2. It consists of tissue that has been decalcified;
- •3. It is a fine needle aspirate or cytology specimen; or
- •4. Cut slides were prepared over 12 months prior to staining
研究者
相似试验
尚未招募
不适用
Clinical Performance Study Protocol for Use of VENTANA PD-L1(SP263) CDx Assay in GSK Study 213823 (GALAXIES LUNG-301)on-Small-Cell-Lung Cancer (NSCLC)locally advancedunresectable or metastatic NSCLC10024967Lung CancerNL-OMON56986Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)10
尚未招募
1 期
Panchakarma, Ayurveda, Emesis, Powder massage, hypothyroidismCTRI/2020/01/022809Dr Mallika Singh
进行中（未招募）
1 期
Clinical study to investigate whether in patients with peripheral artery disease, after implantation of a stent and showing high platelet reactivity during treatment with clopidogrel, treatment with ticagrelor is able to prevent effectively vascular occlusioEUCTR2014-001989-97-ATOA Doz. Dr. Thomas Müller c/o B&S Zentrallabor Konventhospital Barmherzige Brüder Linz500
尚未招募
2 期
Clinical study to see the effect of Vrana Lepa in non-healing ulcersCTRI/2021/01/030398Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
招募中
2 期
A clinical study of Vranari Guggulu and Vrana lepa in the management of Diabetic Foot UlcerCTRI/2015/02/005586DrNRS GovtAyurvedic College100